Los Angeles Capital Management LLC lifted its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) by 57.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 106,479 shares of the company’s stock after purchasing an additional 38,824 shares during the quarter. Los Angeles Capital Management LLC owned 0.23% of Nurix Therapeutics worth $1,169,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Nurix Therapeutics by 23.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,312 shares of the company’s stock valued at $69,000 after purchasing an additional 1,194 shares in the last quarter. ARK Investment Management LLC boosted its stake in Nurix Therapeutics by 54.5% during the fourth quarter. ARK Investment Management LLC now owns 1,988,254 shares of the company’s stock worth $21,831,000 after buying an additional 701,732 shares during the period. Bank of New York Mellon Corp boosted its stake in Nurix Therapeutics by 17.0% during the third quarter. Bank of New York Mellon Corp now owns 158,760 shares of the company’s stock worth $2,069,000 after buying an additional 23,057 shares during the period. Balyasny Asset Management LLC purchased a new position in Nurix Therapeutics during the third quarter worth $208,000. Finally, BNP Paribas Arbitrage SNC purchased a new position in Nurix Therapeutics during the third quarter worth $996,000. 91.33% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
NRIX has been the subject of several recent analyst reports. Stifel Nicolaus dropped their price objective on shares of Nurix Therapeutics from $37.00 to $31.00 and set a “buy” rating for the company in a research note on Tuesday, February 14th. Oppenheimer initiated coverage on Nurix Therapeutics in a research report on Monday, February 27th. They set an “outperform” rating and a $25.00 target price for the company. JPMorgan Chase & Co. decreased their target price on Nurix Therapeutics from $37.00 to $36.00 and set an “overweight” rating for the company in a research report on Monday, February 13th. Royal Bank of Canada restated an “outperform” rating and issued a $30.00 price objective on shares of Nurix Therapeutics in a report on Friday, April 14th. Finally, Needham & Company LLC restated a “buy” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a report on Friday, April 21st. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $29.75.
Nurix Therapeutics Stock Performance
Nurix Therapeutics (NASDAQ:NRIX – Get Rating) last issued its quarterly earnings results on Thursday, February 9th. The company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.19). Nurix Therapeutics had a negative return on equity of 60.17% and a negative net margin of 428.29%. The business had revenue of $6.78 million for the quarter, compared to analysts’ expectations of $19.64 million. On average, equities analysts predict that Nurix Therapeutics, Inc. will post -3.24 earnings per share for the current fiscal year.
Nurix Therapeutics Profile
Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
See Also
- Get a free copy of the StockNews.com research report on Nurix Therapeutics (NRIX)
- Do Bank Stocks Go Up When Interest Rates Rise?
- How to Invest in Vertical Farming Stocks
- Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
- Ecolab: Slow And Steady Wins The Race
- MGM’s Hot Hand Is All In For A Rally, After This Small Break
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
